Climb Bio licenses MIL116 antibodies from Mabworks; reports $212.9M cash, runway through 2027

Climb Bio, Inc.

Upfront $9M to Mabworks; up to $30M development/regulatory milestones for first indication.
Up to $832M commercial milestones across all products; tiered low-to mid-single-digit royalties.
Preliminary cash $212.9M and ~67.3M shares outstanding as of Dec 31, 2024.
Existing cash expected to fund operations, including budoprutug and CLYM116, through 2027.
Exclusive rights to MIL116 (CLYM116) outside China; non-exclusive rights for global trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.